Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moFAMOTIDINE (famotidine) by Bristol Myers Squibb is histamine-2 (h2) receptors. Approved for pathological hypersecretory conditions (e, the risk of duodenal ulcer recurrence, the risk of du recurrence.
Drug data last refreshed 1mo ago
histamine-2 (H2) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.
Worked on FAMOTIDINE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo